• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝硬化性心肌病:对病理生理学、诊断及管理的全面见解

Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.

作者信息

Ndakotsu Andrew, Nduka Tagbo Charles, Agrawal Simran, Asuka Edinen

机构信息

Department of Internal Medicine, MedStar Union Memorial Hospital Baltimore, Baltimore, MD, USA.

Department of Medicine, MedStar Health, Baltimore, MD, USA.

出版信息

Heart Fail Rev. 2025 Mar 12. doi: 10.1007/s10741-025-10500-7.

DOI:10.1007/s10741-025-10500-7
PMID:40069401
Abstract

Cirrhotic cardiomyopathy (CCM) is a cardiac dysfunction linked to chronic liver disease, primarily characterized by impaired cardiac response to stress, despite normal baseline function. It presents with both systolic and diastolic dysfunction, along with electrophysiological changes such as QT interval prolongation. CCM is driven by a combination of systemic inflammation, nitric oxide-induced vasodilation, and neurohormonal dysregulation, leading to myocardial impairment and abnormal vascular responses. Clinically, CCM often remains asymptomatic at rest, but patients may experience exercise intolerance or heart failure during stress. Diagnosis includes echocardiographic evaluation, biomarker analysis (NT-proBNP, troponins), and electrocardiography for detecting electrophysiologic abnormalities. Management is complicated by cirrhosis, limiting the use of conventional heart failure treatments, with liver transplantation being the most definitive intervention in severe cases. Early detection of CCM is vital, particularly for patients undergoing liver transplantation or major surgery, where cardiac complications can increase mortality. Further research is necessary to refine diagnostic criteria and treatment strategies.

摘要

肝硬化性心肌病(CCM)是一种与慢性肝病相关的心脏功能障碍,其主要特征是尽管基线功能正常,但心脏对应激的反应受损。它表现为收缩和舒张功能障碍,以及QT间期延长等电生理变化。CCM是由全身炎症、一氧化氮诱导的血管舒张和神经激素失调共同驱动的,导致心肌损伤和异常的血管反应。临床上,CCM在静息时通常无症状,但患者在应激时可能会出现运动不耐受或心力衰竭。诊断包括超声心动图评估、生物标志物分析(NT-proBNP、肌钙蛋白)以及用于检测电生理异常的心电图检查。由于肝硬化,管理变得复杂,限制了传统心力衰竭治疗方法的使用,肝移植是严重病例中最具决定性的干预措施。早期发现CCM至关重要,特别是对于接受肝移植或大手术的患者,因为心脏并发症会增加死亡率。需要进一步研究以完善诊断标准和治疗策略。

相似文献

1
Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.肝硬化性心肌病:对病理生理学、诊断及管理的全面见解
Heart Fail Rev. 2025 Mar 12. doi: 10.1007/s10741-025-10500-7.
2
Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased?肝硬化性心肌病:肝脏与心肌的相互作用。当肝脏出现疾病时,心血管系统会如何反应?
Curr Cardiol Rev. 2021;17(1):78-84. doi: 10.2174/1573403X15666190509084519.
3
Cirrhotic cardiomyopathy: the liver affects the heart.肝硬化性心肌病:肝脏影响心脏。
Braz J Med Biol Res. 2019 Feb 14;52(2):e7809. doi: 10.1590/1414-431X20187809.
4
Cirrhotic cardiomyopathy.肝硬化性心肌病
Orphanet J Rare Dis. 2007 Mar 27;2:15. doi: 10.1186/1750-1172-2-15.
5
Cirrhotic Cardiomyopathy.肝硬化性心肌病。
Curr Gastroenterol Rep. 2020 Jul 10;22(9):45. doi: 10.1007/s11894-020-00783-1.
6
[Cirrhotic cardiomyopathy].[肝硬化性心肌病]
Dtsch Med Wochenschr. 2021 Aug;146(16):1070-1076. doi: 10.1055/a-1321-9523. Epub 2021 Aug 20.
7
Diagnosis and Management of Cirrhotic Cardiomyopathy.肝硬化性心肌病的诊断与管理
J Clin Exp Hepatol. 2022 Jan-Feb;12(1):186-199. doi: 10.1016/j.jceh.2021.08.016. Epub 2021 Aug 21.
8
New insights into cirrhotic cardiomyopathy.肝硬化性心肌病的新见解。
Int J Cardiol. 2013 Aug 20;167(4):1101-8. doi: 10.1016/j.ijcard.2012.09.089. Epub 2012 Oct 4.
9
Cirrhotic Cardiomyopathy-A Veiled Threat.肝硬化性心肌病——隐匿的威胁。
Cardiol Rev. 2022;30(2):80-89. doi: 10.1097/CRD.0000000000000377.
10
[Cardiomyopathy in liver cirrhosis--an undiagnosed entity?].[肝硬化中的心肌病——一种未被诊断的病症?]
Rev Med Chir Soc Med Nat Iasi. 2010 Apr-Jun;114(2):319-26.

本文引用的文献

1
Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities.肝硬化性心肌病的治疗方法:现状与未来可能。
Int J Mol Sci. 2024 May 28;25(11):5849. doi: 10.3390/ijms25115849.
2
Corrected QT interval in cirrhosis: A systematic review and meta-analysis.肝硬化患者的校正QT间期:一项系统评价与荟萃分析。
World J Hepatol. 2023 Sep 27;15(9):1060-1083. doi: 10.4254/wjh.v15.i9.1060.
3
Comparison of the 2005 Montreal Criteria and the 2019 Cirrhotic Cardiomyopathy Consortium Criteria for the Diagnosis of Cirrhotic Cardiomyopathy.
2005 年蒙特利尔标准与 2019 年肝硬化心肌病联盟标准诊断肝硬化心肌病的比较。
Am J Cardiol. 2023 Dec 1;208:180-189. doi: 10.1016/j.amjcard.2023.09.069. Epub 2023 Oct 16.
4
Diagnosis and Management of Cirrhosis and Its Complications: A Review.肝硬化及其并发症的诊断与管理:综述。
JAMA. 2023 May 9;329(18):1589-1602. doi: 10.1001/jama.2023.5997.
5
Cirrhotic cardiomyopathy: Predictors of major adverse cardiac events and assessment of reversibility after liver transplant.肝硬化性心肌病:肝移植后主要不良心脏事件的预测因子和可逆性评估。
J Cardiol. 2023 Aug;82(2):113-121. doi: 10.1016/j.jjcc.2023.04.007. Epub 2023 Apr 20.
6
Emerging Therapeutic Targets for Portal Hypertension.门静脉高压症的新兴治疗靶点
Curr Hepatol Rep. 2023;22(1):51-66. doi: 10.1007/s11901-023-00598-4. Epub 2023 Feb 11.
7
The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review.噻唑烷二酮类药物在改善非酒精性脂肪性肝病中的作用:一项系统评价
Cureus. 2022 May 27;14(5):e25380. doi: 10.7759/cureus.25380. eCollection 2022 May.
8
Cirrhotic cardiomyopathy: Appraisal of the original and revised criteria in predicting posttransplant cardiac outcomes.肝硬化性心肌病:评估原始和修订标准对移植后心脏结局的预测。
Liver Transpl. 2022 Aug;28(8):1321-1331. doi: 10.1002/lt.26460. Epub 2022 Jun 16.
9
Six-minute walking test performance is associated with survival in cirrhotic patients.六分钟步行试验表现与肝硬化患者的生存率相关。
World J Hepatol. 2021 Nov 27;13(11):1791-1801. doi: 10.4254/wjh.v13.i11.1791.
10
Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death.心肌应激、心肌损伤和亚临床炎症标志物与猝死风险。
Circulation. 2020 Sep 22;142(12):1148-1158. doi: 10.1161/CIRCULATIONAHA.120.046947. Epub 2020 Jul 23.